Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Lissoni

Showing results (131-140 of 287) with videos related to

Pageof 29
Sort By:
Journal of Biological Regulators and Homeostatic Agents|October 1, 1996
Reactivation of a normal endogenous secretion of interleukin-2 in metastatic cancer patients by a chronic subcutaneous injection of interleukin-2G Di Felice, L Fumagalli, F Majorca, et al.
Oncology|November 1, 1993
A study of the mechanisms involved in the immunostimulatory action of the pineal hormone in cancer patientsP Lissoni, S Barni, G Tancini, et al.
British Journal of Cancer|July 17, 1999
Pretreatment serum markers and lymphocyte response to interleukin-2 therapyL Fumagalli, P Lissoni, G Di Felice, et al.
Recenti Progressi in Medicina|June 5, 1998
Endocrine effects of two pineal hormones other than melatonin in healthy volunteers: 5-methoxytryptophol and 5-methoxytryptamineP Lissoni, F Rovelli, L Giani, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
The biological significance of soluble interleukin-2 receptors in solid tumorsP Lissoni, S Barni, F Rovelli, et al.
Journal of Biological Regulators and Homeostatic Agents|October 1, 1992
Inhibitory effect of interleukin-3 on interleukin-2-induced cortisol release in the immunotherapy of cancerP Lissoni, F Rovelli, G Tancini, et al.
Recenti Progressi in Medicina|December 1, 1996
The pineal hormone melatonin in hematology and its potential efficacy in the treatment of thrombocytopeniaP Lissoni, G Tancini, S Barni, et al.
Anticancer Research|April 12, 2003
Antiprolactinemic approach in the treatment of metastatic breast cancer: a phase II study of polyneuroendocrine therapy with LHRH-analogue, tamoxifen and the long-acting antiprolactinemic drug cabergolineP Lissoni, M Vaghi, S Villa, et al.
Giornale Italiano Di Cardiologia|July 1, 1990
[The cardiovascular toxicity of interleukin-2: the pathogenic mechanisms and treatment]P Lissoni, M A Galli, S Barni, et al.
Oncology|March 1, 1995
Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumorsP Lissoni, S Barni, G Tancini, et al.
Pageof 29

Showing results (131-140 of 287) with videos related to

Sort By:
Pageof 29
Journal of Biological Regulators and Homeostatic Agents|October 1, 1996
Reactivation of a normal endogenous secretion of interleukin-2 in metastatic cancer patients by a chronic subcutaneous injection of interleukin-2G Di Felice, L Fumagalli, F Majorca, et al.
Oncology|November 1, 1993
A study of the mechanisms involved in the immunostimulatory action of the pineal hormone in cancer patientsP Lissoni, S Barni, G Tancini, et al.
British Journal of Cancer|July 17, 1999
Pretreatment serum markers and lymphocyte response to interleukin-2 therapyL Fumagalli, P Lissoni, G Di Felice, et al.
Recenti Progressi in Medicina|June 5, 1998
Endocrine effects of two pineal hormones other than melatonin in healthy volunteers: 5-methoxytryptophol and 5-methoxytryptamineP Lissoni, F Rovelli, L Giani, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
The biological significance of soluble interleukin-2 receptors in solid tumorsP Lissoni, S Barni, F Rovelli, et al.
Journal of Biological Regulators and Homeostatic Agents|October 1, 1992
Inhibitory effect of interleukin-3 on interleukin-2-induced cortisol release in the immunotherapy of cancerP Lissoni, F Rovelli, G Tancini, et al.
Recenti Progressi in Medicina|December 1, 1996
The pineal hormone melatonin in hematology and its potential efficacy in the treatment of thrombocytopeniaP Lissoni, G Tancini, S Barni, et al.
Anticancer Research|April 12, 2003
Antiprolactinemic approach in the treatment of metastatic breast cancer: a phase II study of polyneuroendocrine therapy with LHRH-analogue, tamoxifen and the long-acting antiprolactinemic drug cabergolineP Lissoni, M Vaghi, S Villa, et al.
Giornale Italiano Di Cardiologia|July 1, 1990
[The cardiovascular toxicity of interleukin-2: the pathogenic mechanisms and treatment]P Lissoni, M A Galli, S Barni, et al.
Oncology|March 1, 1995
Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumorsP Lissoni, S Barni, G Tancini, et al.
Pageof 29